RED GLEAD DISCOVERY

Red Glead Discovery offers integrated drug discovery services, including design, synthesis, fragment screening, and biological and ADME profiling. The company focuses on small molecules and peptides, with a drug discovery platform covering medicinal chemistry, synthesis, ADME, and biology. Services are complemented by Computational Chemistry, advanced MS and NMR analysis, and standalone offerings. Red Glead excels in fragment-based drug discovery, utilizing its proprietary technique WAC (Weak Affinity Chromatography) alongside other FBDD methods. The company's project management skills and cross-disciplinary capabilities make it a preferred partner for developing high-potential compounds. In addition to its CRO business, Red Glead engages in research collaborations with biotech and academic partners. Founded in 2011 by former Astra Zeneca employees, it currently employs approximately 60 co-workers. Operating in the pharmaceutical industry, Red Glead presents an intriguing investment opportunity with its expertise in drug discovery and strong industry connections.